This webinar provides an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.
Checkpoint immunotherapy has proven to be a powerful therapeutic against a variety of cancers, yet due to response rates that range between 20 percent and 40 percent, researchers and drug developers continue to seek ways to indicate response or non-response as early as possible. A particular area of focus is biomarkers that can assess the status of the pre-therapy tumor microenvironment in order to predict response.
Our speaker, Naval Daver of MD Anderson Cancer Center, discusses advanced immune-based approaches in acute myeloid leukemia that combine chemotherapy with checkpoint therapy, along with the relevant biomarker strategies associated with each.
Dr. Daver also describes a study based on a single-cell cytokine analysis system and Polyfunctional Strength Index (PSI) from Isoplexis that demonstrated that certain cytokine potency contributors, in particular from stimulatory cytokines, correlate with overall survival.
In addition, Jon Chen of Isoplexis shares several case studies using tumor-infiltrating lymphocytes in combination checkpoint immunotherapy that correlate polyfunction to outcome.
*Due to the location of our speakers, this webinar is pre-recorded.